Brief: Ventyx Biosciences Q4 EPS USD -0.41
27/02/2025 21:05
Feb 27 (Reuters) - Ventyx Biosciences Q4 operating expenses USD 32.418 million. Q4 net income USD -29.351 million
Recent news on Ventyx Biosciences
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (updated)
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
Deals of the day-Mergers and acquisitions